ABK Biomedical Concludes Patient Enrollment in Pivotal ROUTE90 Study for Liver Cancer Treatment ABK Biomedical has finalized patient enrollment in the ROUTE90 study. This pivotal clinical trial evaluates the Eye90 microspheres, a potential breakthrough in liver cancer treatment.

ABK Biomedical Concludes Patient Enrollment in Pivotal ROUTE90 Study for Liver Cancer Treatment #Canada #Halifax #ABK_Biomedical #Eye90_microspheres #ROUTE90

ABK Biomedical Secures US$35 Million in Series D Financing to Enhance Medical Device Innovation ABK Biomedical, Inc. has successfully raised US$35 million in a Series D funding round, supporting the development and commercialization of their innovative medical device technologies.

ABK Biomedical Secures US$35 Million in Series D Financing to Enhance Medical Device Innovation #Canada #Halifax #JP_Morgan #ABK_Biomedical #Eye90